Alnylam Pharmaceuticals (ALNY) Named Best 2022 Idea at Cowen

Cowen analyst Ritu Baral reiterated an Outperform rating and $250.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) and named the stock a Best Idea for 2022.

The analyst commented, "ALNY is our top pick for 2022 as it nears a key inflection point: APOLLO-B data of patisiran in TTR-CM (mid-'22). This is set up for success given precedent cardiac subset data from TTR-PN trials. We model $2B+ sales for patisiran/vutrisiran in TTR-CM, achievable given current $2B sales of tafamidis. With profitability on the horizon, ALNY may be a more attractive strategic asset than ever."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $172.63 yesterday.

You May Also Be Interested In

• Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo
• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Analog Devices (ADI) Reiterated at Overweight by Cantor Fitzgerald: Beat and Raise Expected